Robert Grant from the Gladstone Institute of Virology and Immunology San Francisco presented follow-up results from the international iPrEx study.1
The initial analysis published in the NEJM in November 2010 reported a 44% reduction (36 vs 64 infections; 95%CI 15 to 63%; p=0.005) from use of daily oral tenofovir/FTC compared to placebo in 2499 young sexually active MSM at high risk of catching HIV. However, all infections in the active arm of the study were associated with undetectable (91%) or low (9%) drug levels in blood (compared to 51% of uninfected matched cases) indicating higher protection rates (~95%) with actual use.2
Results presented at CROI from an additional final four months of blinded randomised arms included 12 new infections in the active vs 19 in the placebo groups (p=0.002). During follow-up three months after drug/placebo discontinuation there were 4 new infections in the active arm and 2 in the placebo group (p=NS).
By all analyses, these final data retained similar significant protection rates to the initial published results. Protection was seen in all subgroups (by age, ethnicity, region, schooling, alcohol use, circumcision) but greater protection was seen in people reporting higher risks (i.e. unprotected anal intercourse, p=0.03).
Side effects were reported at similar rates in both arms and are summarised in Table 1. Differences in nausea and weight loss were seen in the first four weeks that subsequently resolved to placebo levels. No differences were seen in laboratory safety markers including phosphate, electrolytes, AST, ALT, amylase, glucose etc. While encouraging, these safety data need to be interpreted with consideration of the minimal adherence in each arm suggested by the PK sub-study.
|Table 1: Adverse Events Reported in iPrEx; n (%)|
|Tenofovir / FTC||placebo||P|
|Depression||43 (3%)||62 (5%)||0.07|
|Grade 3/4 events||151 (12%)||164 (13%)||p=0.51|
|Death||1 (<1%)||4 (<1%)||p=0.18|
|Serious AE||60 (5%)||67 (5%)||p=0.57|
|Diarrhoea||46 (4%)||56 (4%)||p=0.36|
|Headache||56 (4%)||41 (3%)||p=0.10|
|Nausea||20 (2%)||9 (<1%)||p=0.04|
|Weight decrease||27 (2%)||14 (1%)||p=0.04|
|Creatinine elevation||25 (2%)||14 (1%)||p=0.08|
|Confirmed Cr increase (0.4%)||5||0||p=0.06|
Drug resistance was not detected in any of the cases of seroconversion that occurred during the study, but resistance to FTC was found in three people who were seronegative at baseline but later found to be recently infected by PCR viral load.
Self-reported risk reductions in behaviour changes in terms of partner reduction and increased condom use should perhaps be considered cautiously given the low correlation between reported and actual adherence.
However, the positive results reported from the study should increase the likelihood for actual adherence in the future. Of interest, despite this optimism, Dr Grant suggested that actual adherence should not be assumed, even knowing when protection is proven.
Participants in iPrEx study are being given the option to enroll in a follow-up study of open label. tenofovir/FTC.
Two studies were presented looking at the impact on bone mineral density during PrEP. These are important both for the opportunity to evaluate the safety of PrEP but also to look at the previously observed side effects of tenofovir separate from an additional impact of both HIV and ageing.
Albert Liu from University of California, San Francisco presented baseline (n=200) and longitudinal (n=184) results from HIV-negative men followed from 2005-2007 in a randomised tenofovir vs placebo study run in San Francisco.3
Demographics and baseline characteristics included: median age 40 years (range 19-60); 77% white, 7% Latino or Hispanic, 5% African American, and 5% Asian or Pacific Islander. Approximately 20% were smokers, 40% with moderate/heavy alcohol use, 15% corticosteroid use and 60% used multivitamin, calcium of vitamin D supplements. At baseline a higher proportion of men were found to have low BMD (defined as z-score > -2.0) than would have been expected (~10%; 20 vs 4.8 cases; p<0.001).
DEXA scans performed at baseline, 9 or 12 months, and 24 months showed -1.1% net decrease in mean BMD in the tenofovir vs placebo group at the femoral neck (95%CI 0.4 to 1.9%, p = 0.004) and a -0.8% net decline at the total hip (95%CI 0.3 to 1.3%, p = 0.003). At the spine (L2 to L4) there was a trend towards a -0.7% difference (95%CI -0.1 to 1.5%, p = 0.11). These results were similar after adjustment for baseline BMD, BMI, race, age, and creatinine clearance.
Declines mainly occurred during the first 12 to 15 months of treatment and were generally small. More significant losses (>3% BDM) occurred more frequently in the tenofovir group for hip and femoral neck (both p=0.02) but this was no longer significant at any location when using a >5% cut off (p=1.0, 0.13 and 0.72; for hip, neck and spine respectively).
The ten reported fractures (six in the active and four in the placebo group; p=0.75) were all trauma-related and judged unrelated to study drug.
In a second study, Kathleen Mulligan from University of California, San Francisco presented hip and spine BMD results measured every 24 weeks in approximately 500 people enrolled in a substudy of iPrEx.4
Participant were enrolled from sites in Peru (n=221), Thailand (n=95), the US (n=71), South Africa (n=61) and Brazil (n=55) and resulted in broader ethnicity: 18% were Caucasian, 13% black, 20% Asian, 49% mixed race; 52% were Hispanic or Latino. This was a younger population: 48% were under 25 years old and therefore likely to still be experiencing bone mass growth.
Although >60% were active (weight bearing exercise), alcohol (80%) and tobacco (43%) use was common. Mean body mass index was 23.5 (SE 0.2) kg/m2. At baseline, total age and race adjusted z-score for the group which would be expected to be 1.0 was negatively shifted to the left. Low bone mineral density (z-score < -1.0/-2.0) was seen in 36%/12% people in the spine and 18%/2% in the hip, with no difference between the active and placebo groups. Unfortunately there are limited studies of bone disease in otherwise healthy young men to verify the normative data used in bone studies, however the same data are used when evaluating low BMD related to HIV, where similar or greater rates of low BMD are commonly reported.
During the study, bone mineral density tended to increase in the placebo arm and decrease in the FTC/TDF arm, resulting in modest (-0.7 to -1.0%) but statistically significant differences between the groups by week 24 (see Table 2). These are lower than the -2 to -4% seen in HIV-positive people starting tenofovir-containing HAART. Lower patient numbers at later timepoints will require later analyses.
While these are encouraging data, it was also pointed out that it would not be expected to see differences in young healthy men, although limited drug exposure due to low treatment adherence, will also have diluted any reductions caused by tenofovir.
|Table 2: Mean (SE) Percent Change in Bone Mineral Density From Enrollment|
|FTC/TDF||Placebo||Difference (95%CI)||p value|
|week 24||-0.31 (0.13)||+0.34 (0.13)||-0.65
(-1.03 to -0.28)
|week 48||-0.05 (0.22)||+0.90 (0.22)||-0.95
(-1.56 to -0.35)
|week 72||+0.27 (0.28)||+0.49 (0.28)||-0.22
(-1.00 to 0.56)
|week 24||-0.66 (0.20)||+0.29 (0.20)||-0.95
(-1.51 to -0.39)
|week 48||-0.41 (0.24)||+0.13 (0.24)||-0.54
(-1.20 to 0.12)
|week 72||-0.97 (0.32)||-0.10 (0.32)||-0.87
(-1.75 to -0.01)
No comments have been made.
|Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.|